Skip to Main content Skip to Navigation
New interface
Journal articles

Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects

Abstract : Hydroxyurea (HU), an FDA-approved drug for treating sickle cell disease, is used as an antitumor drug alone and together with conventional chemotherapeutics or radiation therapy. HU is used primarily to treat myeloproliferative diseases because it inhibits the enzyme ribonucleotide reductase involved in DNA synthesis. The hydroxyl group in HU is considered critical for its antiproliferative and chemotherapeutic effects. Here, we substituted the hydroxyl group in HU with a triphenylphosphonium cation attached to an alkyl group with different chain lengths, forming a new class of mitochondria-targeted HU (Mito-HU). Elongating the alkyl side chain length increased the hydrophobicity of Mito-HUs, inhibition of oxidative phosphorylation, and antiproliferative effects in tumor cells. Both mitochondrial complex I-and complex III-induced oxygen consumption decreased with the increasing hydrophobicity of Mito-HUs. The more hydrophobic Mito-HUs also potently inhibited the monocytic myeloid-derived suppressor cells and suppressive neutrophils, and stimulated T cell response, implicating their potential antitumor immunomodulatory mechanism.
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03627839
Contributor : Emilie PEPE Connect in order to contact the contributor
Submitted on : Friday, April 1, 2022 - 3:11:35 PM
Last modification on : Tuesday, April 5, 2022 - 3:37:22 AM

File

pub2mica2021.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Gang Cheng, Micael Hardy, Paytsar Topchyan, Ryan Zander, Peter Volberding, et al.. Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects. iScience, 2021, ⟨10.1016/j.isci.2021.102673⟩. ⟨hal-03627839⟩

Share

Metrics

Record views

15

Files downloads

26